We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
Read MoreHide Full Article
Key Takeaways
Wave Life Sciences stock sank 49.6% after interim phase I data on WVE-007 disappointed investors.
WVE-007 showed 14% visceral fat drop at 240 mg, but the 400 mg dose delivered more modest interim results.
WVE plans phase IIa study in Q2 2026, with more data and new studies expected later in 2026.
Shares of Wave Life Sciences (WVE - Free Report) plunged 49.6% yesterday after the company announced new data from the phase I portion of the INLIGHT study evaluating its investigational pipeline candidate, WVE-007, in otherwise healthy individuals who are overweight or living with obesity.
What Did WVE’s Latest Data Show?
Data from this study showed that after six months of follow-up, a single 240 mg dose of WVE-007 demonstrated sustained benefits compared to placebo, including a statistically significant 14% reduction in visceral fat and a 5% reduction in total body fat. Lean mass remained stable with a 2% increase, while additional improvements were observed in waist circumference, which decreased by 3%, and overall body weight, which declined by 1%.
However, in the 400 mg group, three-month results showed a 5% reduction in visceral fat and a 0.7% decline in total fat versus placebo following a single dose of WVE-007. Lean mass remained largely unchanged, with a negligible 0.2% decrease, suggesting preservation of muscle, though overall fat reduction was relatively modest at this interim stage.
This might have hurt investors' sentiments and resulted in the stock declining following the announcement of the news.
Treatment with WVE-007 led to greater improvement in body composition, as measured by the visceral fat-to-muscle ratio, at six months compared with weekly GLP-1 therapies evaluated in later-stage studies.
Treatment with WVE-007 was generally safe and well-tolerated to date, up to 600 mg.
Year to date, shares of Wave Life Sciences have plunged 63.5% against the industry’s rise of 1.6%.
Image Source: Zacks Investment Research
WVE Other Development Activities With WVE-007
The company is gearing up to initiate the phase IIa multidose portion of the INLIGHT study in the second quarter of 2026. This part of the study will evaluate WVE-007 as a monotherapy in individuals with higher BMI (35–50 kg/m²) and associated comorbidities.
Data from this study will inform further development of WVE-007 in obesity as well as metabolic dysfunction-associated steatohepatitis (MASH), type II diabetes, and cardiovascular disease.
Additional data from the INLIGHT study, including results from the 600 mg of WVE-007 phase I single ascending dose (SAD) cohort, are expected later in 2026.
The company also plans to initiate a new clinical study evaluating WVE-007 as an incretin add-on and as post-incretin maintenance later in 2026.
Stiff Competition in the Obesity Space
The obesity market has garnered significant attention over the past few years due to the sizable and still underpenetrated market opportunity. Currently, Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) dominate this space with their respective injectable therapies.
Eli Lilly and Novo Nordisk are trying to gain an upper hand in oral weight-loss pills. In late December, the FDA approved an oral version of NVO’s Wegovy. The drug was commercially launched in early January. The approval made Wegovy the first GLP-1 therapy available as a pill for weight management, offering a needle-free alternative that could expand patient adoption. A regulatory filing seeking approval for Eli Lilly’s obesity pill orforglipron is currently under review by the FDA, with a final decision expected soon.
Several other companies, like Viking Therapeutics (VKTX - Free Report) , are also making rapid progress in the obesity space. Last year, VKTX started two late-stage studies evaluating the subcutaneous formulation of its investigational obesity drug, VK2735. While one of these studies completed enrolment at a rapid pace, VKTX recently completed enrolment in the other study, too.
View the Zacks #1 Rank List
Image: Bigstock
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
Key Takeaways
Shares of Wave Life Sciences (WVE - Free Report) plunged 49.6% yesterday after the company announced new data from the phase I portion of the INLIGHT study evaluating its investigational pipeline candidate, WVE-007, in otherwise healthy individuals who are overweight or living with obesity.
What Did WVE’s Latest Data Show?
Data from this study showed that after six months of follow-up, a single 240 mg dose of WVE-007 demonstrated sustained benefits compared to placebo, including a statistically significant 14% reduction in visceral fat and a 5% reduction in total body fat. Lean mass remained stable with a 2% increase, while additional improvements were observed in waist circumference, which decreased by 3%, and overall body weight, which declined by 1%.
However, in the 400 mg group, three-month results showed a 5% reduction in visceral fat and a 0.7% decline in total fat versus placebo following a single dose of WVE-007. Lean mass remained largely unchanged, with a negligible 0.2% decrease, suggesting preservation of muscle, though overall fat reduction was relatively modest at this interim stage.
This might have hurt investors' sentiments and resulted in the stock declining following the announcement of the news.
Treatment with WVE-007 led to greater improvement in body composition, as measured by the visceral fat-to-muscle ratio, at six months compared with weekly GLP-1 therapies evaluated in later-stage studies.
Treatment with WVE-007 was generally safe and well-tolerated to date, up to 600 mg.
Year to date, shares of Wave Life Sciences have plunged 63.5% against the industry’s rise of 1.6%.
Image Source: Zacks Investment Research
WVE Other Development Activities With WVE-007
The company is gearing up to initiate the phase IIa multidose portion of the INLIGHT study in the second quarter of 2026. This part of the study will evaluate WVE-007 as a monotherapy in individuals with higher BMI (35–50 kg/m²) and associated comorbidities.
Data from this study will inform further development of WVE-007 in obesity as well as metabolic dysfunction-associated steatohepatitis (MASH), type II diabetes, and cardiovascular disease.
Additional data from the INLIGHT study, including results from the 600 mg of WVE-007 phase I single ascending dose (SAD) cohort, are expected later in 2026.
The company also plans to initiate a new clinical study evaluating WVE-007 as an incretin add-on and as post-incretin maintenance later in 2026.
Stiff Competition in the Obesity Space
The obesity market has garnered significant attention over the past few years due to the sizable and still underpenetrated market opportunity. Currently, Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) dominate this space with their respective injectable therapies.
Eli Lilly and Novo Nordisk are trying to gain an upper hand in oral weight-loss pills. In late December, the FDA approved an oral version of NVO’s Wegovy. The drug was commercially launched in early January. The approval made Wegovy the first GLP-1 therapy available as a pill for weight management, offering a needle-free alternative that could expand patient adoption. A regulatory filing seeking approval for Eli Lilly’s obesity pill orforglipron is currently under review by the FDA, with a final decision expected soon.
Several other companies, like Viking Therapeutics (VKTX - Free Report) , are also making rapid progress in the obesity space. Last year, VKTX started two late-stage studies evaluating the subcutaneous formulation of its investigational obesity drug, VK2735. While one of these studies completed enrolment at a rapid pace, VKTX recently completed enrolment in the other study, too.
WAVE Life Sciences Ltd. Price
WAVE Life Sciences Ltd. price | WAVE Life Sciences Ltd. Quote
WVE’s Zacks Rank
Wave Life Sciences currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.